Contribution of alpha‐synuclein pathology to cerebral glucose metabolism in patients with amnestic MCI
Alzheimer's & Dementia · 2024
DOI: 10.1002/alz.14151 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2024. Verfasst von Samir Abu-Rumeileh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany. Hauptthemen laut MEDLINE: alpha-Synuclein, Cognitive Dysfunction, Glucose. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, German Federal Ministry of Education and Research, Medical Faculty of Martin-Luther-University of Halle-Wittenberg.
Abstract (Originalsprache)
INTRODUCTION The in vivo detection of mixed Alzheimer's disease (AD) and α‐synuclein (αSyn) pathology is important for clinical management and prognostic stratification. We investigated the contribution of αSyn pathology, detected by cerebrospinal fluid (CSF) seed amplification assay (αSyn SAA), on [18F]‐fluorodeoxyglucose positron emission tomography (FDG PET) pattern in subjects with amnestic mild cognitive impairment (aMCI). METHODS We included 562 aMCI participants and 204 cognitively normal controls (CN) with available αSyn SAA and cerebral metabolic rate for glucose utilization (rCMRgl) data. RESULTS 24% of aMCI cases were positive (+) for CSF αSyn SAA. Compared to CN, both αSyn+ and negative (−) aMCI participants showed reductions in rCMRgl within AD typical regions. αSyn+ aMCI had lower rCMRgl within AD and dementia with Lewy bodies (DLB) typical regions compared to αSyn− aMCI, even after stratification according to the CSF AT(N) system. DISCUSSION αSyn pathology contributes to a distinct FDG PET pattern in aMCI. Highlights αSyn pathology can be detected in vivo by CSF αSyn SAA. We investigated the FDG PET pattern in aMCI patients with CSF αSyn SAA positivity. αSyn+ aMCI showed a marked brain hypometabolism in AD and DLB typical regions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
- Banner Alzheimer's Institute, Phoenix, Arizona, USA.
- Arizona Alzheimer's Consortium, Phoenix, Arizona, USA.
- Department of Psychiatry, College of Medicine, University of Arizona, Phoenix, Arizona, USA.
- Neurogenomics Division, Translational Genomics Research Institute, Phoenix, Arizona, USA.
- Arizona State University-Banner Health Neurodegenerative Disease Research Center, Arizona State University, Tempe, Arizona, USA.
ORCID-Profile: Samir Abu-Rumeileh
Förderung
- NIA NIH HHS
- German Federal Ministry of Education and Research
- Medical Faculty of Martin-Luther-University of Halle-Wittenberg
Zitieren
APA
Abu-Rumeileh, S., Arajyan, G., Reiman, E. M., Otto, M., Weise, C. M., & Alzheimer's Disease Neuroimaging Initiative (2024). Contribution of alpha‐synuclein pathology to cerebral glucose metabolism in patients with amnestic MCI. Alzheimer's & Dementia. https://doi.org/10.1002/alz.14151
Vancouver
Abu-Rumeileh S, Arajyan G, Reiman EM, Otto M, Weise CM, Alzheimer's Disease Neuroimaging Initiative. Contribution of alpha‐synuclein pathology to cerebral glucose metabolism in patients with amnestic MCI. Alzheimer's & Dementia. 2024. doi:10.1002/alz.14151
BibTeX
@article{AbuRumeileh2024,
author = {Abu-Rumeileh, Samir and Arajyan, Garegin and Reiman, Eric M and Otto, Markus and Weise, Christopher M and Alzheimer's Disease Neuroimaging Initiative, Alzheimer's Disease Neuroimaging Initiative},
title = {Contribution of alpha‐synuclein pathology to cerebral glucose metabolism in patients with amnestic MCI},
journal = {Alzheimer's & Dementia},
year = {2024},
doi = {10.1002/alz.14151}
}
EUVIMED